9 Meters Biopharma
NMTR
NMTR was delisted on the 25th of July, 2023.
101 hedge funds and large institutions have $45.2M invested in 9 Meters Biopharma in 2022 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 20 increasing their positions, 32 reducing their positions, and 16 closing their positions.
540% more call options, than puts
Call options by funds: $1.57M | Put options by funds: $246K
3% less funds holding
Funds holding: 104 → 101 (-3)
19% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 16
38% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 32
41% less capital invested
Capital invested by funds: $76.6M → $45.2M (-$31.4M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.53M |
| 2 |
D.E. Shaw & Co
New York
|
+$263K |
| 3 |
RWP
RWA Wealth Partners
Newton,
Massachusetts
|
+$114K |
| 4 |
State Street
Boston,
Massachusetts
|
+$62.7K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$26.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
-$4.24M |
| 2 |
Truist Financial
Charlotte,
North Carolina
|
-$171K |
| 3 |
BlackRock
New York
|
-$119K |
| 4 |
VF
Virtu Financial
New York
|
-$108K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$107K |
NMTR Hedge Fund Activity: Q1 2022 in Review
101 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in 9 Meters Biopharma (NMTR) for Q1 2022, worth a combined $45.2M — down 41% from $76.6M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of NMTR and 13 opened new positions — a net loss of 3 holders — while 32 trimmed existing stakes and 20 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $1.53M. The largest seller was Velan Capital Investment Management, exiting entirely with an estimated $4.24M sold.
- 101 institutional investors held 9 Meters Biopharma (NMTR) as of Q1 2022, down from 104 in Q4 2021.
- Funds reported $45.2M of 9 Meters Biopharma stock for Q1 2022, down 41% quarter-over-quarter.
- 13 funds opened new 9 Meters Biopharma positions in Q1 2022 and 16 closed out, a net change of -3 holders.
- The largest 9 Meters Biopharma buyer in Q1 2022 was Renaissance Technologies, an estimated $1.53M added.
- The largest 9 Meters Biopharma seller in Q1 2022 was Velan Capital Investment Management, an estimated $4.24M sold.
Based on aggregated 13F filings for Q1 2022.